Physician profile
Salem Lebada
NPI 1124694625
$7,049.21
in general payments reported to CMS, 2019-2025
10 companies · $2,626 in 2025
The $2,626 reported for 2025 was more than what 88% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $40.00 · 2024: $4,383 · 2025: $2,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,877 · Travel and Lodging: $3,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.15 |
| Travel and Lodging | $3,172.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,344.49 | 2023-2025 | Ortholoc 3di, Ortholoc 2 Lapifuse, Variax |
| Arthrex, INC. | $1,181.97 | 2025 | |
| Saxum Surgical, INC. | $1,029.12 | 2025 | |
| Biotissue Holdings INC. | $991.65 | 2024-2025 | |
| Bioventus LLC | $203.74 | 2024-2025 | Exogen Ultrasound Bone Healing System |
| Mimedx Group, INC. | $125.82 | 2024 | |
| Treace Medical Concepts, INC. | $99.21 | 2024-2025 | |
| Flower Orthopedics Coporation | $25.50 | 2025 | |
| Globus Medical, INC. | $23.86 | 2025 | Senza |
| Polynovo North America LLC | $23.85 | 2025 | Novosorb Btm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salem Lebada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.